SBFMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	31.81M
平均出来高	1.64M
時価総額	944 803
EPS	$0 ( 2024-04-02 )
次の収益日	( $-8.00 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0.0130 (1.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Slilaty Steve N.	Buy	100 000	Series B Preferred Stock
2024-02-08	Slilaty Steve N.	Buy	20 000	Series B Preferred Stock
2024-01-26	Beaudoin Marc	Buy	0
2022-11-30	Sebaaly Camille	Buy	30 000	Common Stock
2022-10-20	Chamoun Malek	Sell	0	Common Stock, par value $0.001 per share

INSIDER POWER
100.00
Last 67 transactions
Buy: 1 074 426 098 \| Sell: 315 420 609

ボリューム相関

長: 0.19 (neutral)

短: 0.90 (strong)

Signal:(34.554) Same movement expected

Sunshine Biopharma, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sunshine Biopharma, Inc. 相関 - 通貨/商品

0.79
( moderate )

0.70
( moderate )

0.00
( neutral )

0.72
( moderate )

0.00
( neutral )

0.25
( neutral )

Sunshine Biopharma, Inc. 財務諸表

Annual	2023
収益:	$24.09M
総利益:	$8.19M (33.99 %)
EPS:	$-0.190

FY	2023
収益:	$24.09M
総利益:	$8.19M (33.99 %)
EPS:	$-0.190

FY	2022
収益:	$4.35M
総利益:	$1.70M (39.04 %)
EPS:	$-1.760

FY	2021
収益:	$228 426
総利益:	$110 596 (48.42 %)
EPS:	$-0.0609

Financial Reports:

No articles found.

Sunshine Biopharma, Inc.

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.